The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin - Wikidata - awgldk - TriplyDB

The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin

The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin

http://www.wikidata.org/entity/Q24676808

about

Hemopressin is an inverse agonist of CB1 cannabinoid receptors Cannabinoid modulation of noradrenergic circuits: implications for psychiatric disorders The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells TRP channels and traffic-related environmental pollution-induced pulmonary disease β-Arrestin-2 desensitizes the transient receptor potential vanilloid 1 (TRPV1) channel.Interaction Between the Cannabinoid and Vanilloid Systems on Anxiety in Male Rats.In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liability Combined analgesics in (headache) pain therapy: shotgun approach or precise multi-target therapeutics?Cannabinoid WIN 55,212-2 regulates TRPV1 phosphorylation in sensory neurons.Regulation of MMP-9 by a WIN-binding site in the monocyte-macrophage system independent from cannabinoid receptors.Reciprocal changes in vanilloid (TRPV1) and endocannabinoid (CB1) receptors contribute to visceral hyperalgesia in the water avoidance stressed rat.Corticosterone mediates reciprocal changes in CB 1 and TRPV1 receptors in primary sensory neurons in the chronically stressed rat.PP2B/calcineurin-mediated desensitization of TRPV1 does not require AKAP150.Orofacial pain Local activation of cannabinoid CB₁ receptors in the urinary bladder reduces the inflammation-induced sensitization of bladder afferents.Desensitization of transient receptor potential ankyrin 1 (TRPA1) by the TRP vanilloid 1-selective cannabinoid arachidonoyl-2 chloroethanolamine Cannabinoid receptor antagonists AM251 and AM630 activate TRPA1 in sensory neurons.Cannabinoid receptor activation inhibits cell cycle progression by modulating 14-3-3β.Serotonin increases the functional activity of capsaicin-sensitive rat trigeminal nociceptors via peripheral serotonin receptors.Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors.Anti-hyperalgesic effects of anti-serotonergic compounds on serotonin- and capsaicin-evoked thermal hyperalgesia in the rat.Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors.Pain and stress in a systems perspective: reciprocal neural, endocrine, and immune interactions.Inflammatory mediators modulating the transient receptor potential vanilloid 1 receptor: therapeutic targets to treat inflammatory and neuropathic pain.Modulation of breast cancer cell viability by a cannabinoid receptor 2 agonist, JWH-015, is calcium dependent.Overexpression of artemin in the tongue increases expression of TRPV1 and TRPA1 in trigeminal afferents and causes oral sensitivity to capsaicin and mustard oil.ThermoTRP channels in nociceptors: taking a lead from capsaicin receptor TRPV1 The non-selective cannabinoid receptor agonist WIN 55,212-2 attenuates responses of C-fiber nociceptors in a murine model of cancer pain Differential effects of the cannabinoid receptor agonist, WIN 55,212-2, on lamina I and lamina V spinal trigeminal nucleus caudalis neurons Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia Constitutive activity at the cannabinoid CB1 receptor is required for behavioral response to noxious chemical stimulation of TRPV1: antinociceptive actions of CB1 inverse agonists.The therapeutic potential of novel cannabinoid receptors Inhibition of interleukin-1β-induced endothelial tissue factor expression by the synthetic cannabinoid WIN 55,212-2.Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas.Constitutive activity at the cannabinoid CB(1) receptor and behavioral responses.Neurotrophins, endocannabinoids and thermo-transient receptor potential: a threesome in pain signalling.Novel targets for Spinal Cord Injury related neuropathic pain.TRPV1 and TRPA1 in cutaneous neurogenic and chronic inflammation: pro-inflammatory response induced by their activation and their sensitization.

P2860

Q24683759-0C468684-7283-4094-A47B-E1F650DA7DC0 Q27001139-34FA6E36-AE73-43D9-B971-8349A5745A9A Q28236199-80263F4D-A8CF-4888-BF19-0B27AA0C808A Q28396218-C8E5C73A-91FD-4E11-BCC0-643ED709F169 Q30448011-1F4E9D98-9DCC-418C-8D23-43F7A4D4B8F7 Q33716706-97506CF9-1F42-4A68-A41F-AC67F79EDC75 Q33751118-5E460960-AE5F-4F53-993A-DDB51A8ABD3D Q33859031-D152CF6B-3910-4898-9359-F14A3C517F65 Q34023746-73F1CAA3-0C58-4EAC-BE1D-D66E240A0980 Q34471928-7B24CF13-D3F5-4DCB-9E2C-2C0219276DA0 Q34536089-A7E99109-A3F8-4952-A3D9-9BF8A3D667C8 Q34543343-4280C33F-C13B-4467-A7E4-ABBFE354ECAB Q34631957-83E70A26-4460-4EF5-BCA5-299FCE874B57 Q34801865-0CAA9483-2054-4A45-A82F-C2AA4C158D55 Q35047740-DE4B1BD0-261B-4E91-9E24-DFC2C54066F0 Q35080472-195C4DC8-938B-4648-A02F-6D852D8AD69C Q35087509-FA62DC0C-561B-43D3-87F3-BCB08F2DAFA3 Q35202838-24B1F1A9-9DA8-45E3-B1DD-2464AA9849C2 Q35243998-75469311-DAD3-48B2-818E-AE4FC28D2F36 Q35499568-DA48E550-7EB1-48BE-A0C5-2FD86E84A26C Q35740152-CAD7226D-B1FD-4717-83BF-E69DF04A4C1B Q36248857-24E8EBD4-B15C-4E0A-8DA9-71FF5D51A4EA Q36290401-38632DF8-FA4D-4BE6-AD3E-86F0F03B86F2 Q36447081-6AFA800F-4BE8-4805-AC7C-9179C3F63AB7 Q36515510-A83E2649-F0B2-44E6-A756-422082C9BCB9 Q36734927-95098E41-C35A-4584-A190-68506022DFE6 Q36843205-FCFC339C-31F0-4D62-81AF-C0B8F3DBEE66 Q36944550-6C26EA20-C2D5-4C06-9E9B-CC1277B49B27 Q37104144-41C1721E-A9B0-4293-8715-7DDB4D8E9FB4 Q37120771-90248C82-0DAD-44B0-9F4E-FB9C37F392AC Q37284886-8688772B-B9F2-4F10-A5C4-594891865621 Q37345438-674D9728-847C-450B-81A6-B040E589EA03 Q37347537-D04C9AD6-BE9D-409C-ADE8-700857155F2D Q37402927-21BDFF11-300E-4C80-817D-E6EEF450FCAE Q37641624-118439F8-BA6D-4104-9D0B-4B88D62E95AD Q37752096-0F1D735D-F22D-41FE-B97A-9CAD824643F5 Q37805184-BF4E0DC8-4394-44B7-8061-2EFC6C1F76D8 Q38185067-7E3C874E-11B8-469A-A3EA-3EEEE84031C8 Q38247946-29254AA9-EF7C-4BEA-B91B-2F3341D143DD Q39212353-8CAA4A65-58E4-46BD-AA1E-7CE915207BF4

P2860

The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin

http://www.wikidata.org/entity/Q24676808

description

2006 nî lūn-bûn

@nan

2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

The cannabinoid WIN 55,212-2 i ...... tihyperalgesia via calcineurin

@ast

The cannabinoid WIN 55,212-2 i ...... tihyperalgesia via calcineurin

@en

The cannabinoid WIN 55,212-2 i ...... tihyperalgesia via calcineurin

@en-gb

The cannabinoid WIN 55,212-2 i ...... tihyperalgesia via calcineurin

@nl

type

label

The cannabinoid WIN 55,212-2 i ...... tihyperalgesia via calcineurin

@ast

The cannabinoid WIN 55,212-2 i ...... tihyperalgesia via calcineurin

@en

The cannabinoid WIN 55,212-2 i ...... tihyperalgesia via calcineurin

@en-gb

The cannabinoid WIN 55,212-2 i ...... tihyperalgesia via calcineurin

@nl

prefLabel

The cannabinoid WIN 55,212-2 i ...... tihyperalgesia via calcineurin

@ast

The cannabinoid WIN 55,212-2 i ...... tihyperalgesia via calcineurin

@en

The cannabinoid WIN 55,212-2 i ...... tihyperalgesia via calcineurin

@en-gb

The cannabinoid WIN 55,212-2 i ...... tihyperalgesia via calcineurin

@nl

P1433

Q24676808-19FE2728-A9CB-4F52-B21C-637491C8A887

P1476

Q24676808-8D50DA92-BDAC-430A-B4FC-771408B084BD

P2093

Q24676808-3AB10751-32A2-4F98-A1A2-4D042C622BA0

Q24676808-6E76A038-A4E8-4219-9ED3-EF3A1DD77CDC

Q24676808-CB9E707E-B91F-4645-A6C4-7D1E48AB5BF2

Q24676808-CDE0092A-1A91-457E-8276-C38D030EC9C5

P2860

Q24676808-01CAC7D2-393F-44ED-BDB7-B257F2588262

Q24676808-03153C21-89CA-4727-BC32-68280DCCA8CC

Q24676808-03BB3B72-C253-4982-AF84-FD96E767F8EC

Q24676808-09478D2F-B6C2-4745-8D07-154C390F1C71

Q24676808-096F30CE-7361-4DF4-9CDC-802181BF1E86

Q24676808-09B6366A-54B6-4F4C-9354-3ED369F8949B

Q24676808-1B055755-535D-417B-A364-40A54D913304

Q24676808-2886DDF6-3C9E-4C52-91B7-0C47E9BF9014

Q24676808-2C243615-4ECA-4D5C-BF51-654B6181BDCC

Q24676808-2D4C6F15-9C2F-4C25-B6D0-D675BA599742

P304

Q24676808-2EBA3D61-A90E-4AEA-A809-C27298C40770

P31

Q24676808-3FF9A5D9-2B88-44DE-924F-639F36B069B9

P3181

Q24676808-9346A5BD-F5B2-4C01-A094-7A68EBB455DC

P356

Q24676808-78B70A2C-04C9-4C33-A79F-AE1BC960757E

P407

Q24676808-A9FF0FBC-B6F8-4695-937D-C4863DBCB12B

P433

Q24676808-24EA0E44-4F97-4768-9543-F31BDFD962DF

P478

Q24676808-A87F6BF2-DEB8-41E4-B4D0-8EB098BBB1F9

P50

Q24676808-7543BD53-E27B-4832-8208-EEDF94C2D708

Q24676808-B3268821-0EA0-436C-AE23-8CC62F1582EB

P577

Q24676808-BC2382C5-DC6D-42C5-9F41-79364F3FCA4B

P5875

Q24676808-75C4385D-81E6-4D18-A684-2531CA5C6CAE

P698

Q24676808-D078C61E-CFEF-41D0-9926-56F2A9807B7D

P921

Q24676808-3FBD6BC9-2D47-4ECB-8E90-44BD9658FC22

Q24676808-628683c7-9508-4c50-86d4-f88b77f94377

Q24676808-77F7FDC2-47F3-4968-A04E-274E26624479

P932

Q24676808-BA601F34-287F-47EC-8E3E-7DED211F7D14

P3181

P356

PNAS.0603861103

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

The cannabinoid WIN 55,212-2 i ...... tihyperalgesia via calcineurin

@en

P2093

Amol M Patwardhan

http://www.w3.org/2001/XMLSchema#string

Armen N Akopian

http://www.w3.org/2001/XMLSchema#string

Kenneth M Hargreaves

http://www.w3.org/2001/XMLSchema#string

Nathaniel A Jeske

http://www.w3.org/2001/XMLSchema#string

P2860

CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids

Structural determinant of TRPV1 desensitization interacts with calmodulin

Induction of vanilloid receptor channel activity by protein kinase C

Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia

Structure of a cannabinoid receptor and functional expression of the cloned cDNA

Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide

TRPV1 and CB(1) receptor-mediated effects of the endovanilloid/endocannabinoid N-arachidonoyl-dopamine on primary afferent fibre and spinal cord neuronal responses in the rat

Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors

Molecular characterization of a peripheral receptor for cannabinoids

Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide

P304

11393-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2275782

http://www.w3.org/2001/XMLSchema#string

P356

10.1073/PNAS.0603861103

http://www.w3.org/2001/XMLSchema#string

P407

P433

30

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P50

Theodore J. Price

P577

2006-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6937259

http://www.w3.org/2001/XMLSchema#string

P698

16849427

http://www.w3.org/2001/XMLSchema#string

P921

cannabinoid receptor

P932

1544096

http://www.w3.org/2001/XMLSchema#string